跳至主要内容
临床试验/JPRN-UMIN000007785
JPRN-UMIN000007785招募中2 期

The efficacy, safety, and the predictive factors of efficacy of low dose Lenalidomide plus Dexamethasone consolidation therapy followed by very low dose Lenalidomide maintenance therapy for multiple myeloma. - The efficacy, safety, and the predictive factors of efficacy of rd therapy

ational Hospital Organization Disaster Medical Center0 个研究点目标入组 35 人开始时间: 2012年4月19日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • The exclusion criteria were a serum creatinine level>2.05 mg/dL, liver dysfunction (e.g., a serum total bilirubin level>2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (>grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.

研究者

发起方
ational Hospital Organization Disaster Medical Center

相似试验